Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Daver, Naval, Cortes, Jorge, Newberry, Kate, Jabbour, Elias, Zhou, Lingsha, Wang, Xuemei, Pierce, Sherry, Kadia, Tapan, Sasaki, Koji, Borthakur, Gautam, Ravandi, Farhad, Pemmaraju, Naveen, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004422/
https://ncbi.nlm.nih.gov/pubmed/26088933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.126821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados